ReviewCardiovascular drugs and therapy2009
Biology of secretory phospholipase A2.
Review in Cardiovascular drugs and therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- The Phospholipase AJournal of lipid and atherosclerosis · 2026Review
- Metabolic pathways of eicosanoids-derivatives of arachidonic acid and their significance in skin.Cellular & molecular biology letters · 2025Review
- A simultaneous analysis strategy of glycerophospholipids and lipid mediators based on secondary extraction scheme.Analytical and bioanalytical chemistry · 2025Article
- Secreted Phospholipases A2: Drivers of Inflammation and Cancer.International journal of molecular sciences · 2024Review
- Revisiting the reaction pathways for phospholipid hydrolysis catalyzed by phospholipase A2 with QM/MM methods.Chemical science · 2024Article
- Low-Affinity NMDA Receptor Antagonist Hemantane in a Topical Formulation Attenuates Arthritis Induced by Freund's Complete Adjuvant in Rats.Advanced pharmaceutical bulletin · 2024Article
- Integrated Metabolomics and Network Pharmacology Study on the Mechanism ofDrug design, development and therapy · 2024Article
- Article
- Suilyin Disrupts the Blood-Brain Barrier by Activating Group III Secretory Phospholipase A2.Life (Basel, Switzerland) · 2022Article
- Biological Evaluation, Molecular Docking Analyses, and ADME Profiling of Certain New Quinazolinones as Anti-colorectal Agents.ACS omega · 2022Article
- Non-Targeted Metabolomic Profiling of Coronary Heart Disease Patients With Taohong Siwu Decoction Treatment.Frontiers in pharmacology · 2020Article
- Article
- Article
- A Non-Targeted Liquid Chromatographic-Mass Spectrometric Metabolomics Approach for Association with Coronary Artery Disease: An Identification of Biomarkers for Depiction of Underlying Biological Mechanisms.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
- Secretory phospholipase-A2 and fatty acid composition in oral reactive lesions: a cross-sectional study.Cancer cell international · 2017Article
- Biochemical, cell biological, pathological, and therapeutic aspects of Krabbe's disease.Journal of neuroscience research · 2016Review
- Inflammation-associated changes in lipid composition and the organization of the erythrocyte membrane.BBA clinical · 2016Article
- Ectopically expressed pro-group X secretory phospholipase A2 is proteolytically activated in mouse adrenal cells by furin-like proprotein convertases: implications for the regulation of adrenal steroidogenesis.The Journal of biological chemistry · 2015Article
- Acidification of the intimal fluid: the perfect storm for atherogenesis.Journal of lipid research · 2015Review
- Large-scale metabolomic profiling identifies novel biomarkers for incident coronary heart disease.PLoS genetics · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe secretory phospholipase A(2) (sPLA(2)) family provides a seemingly endless array of potential biological functions that is only beginning to be appreciated. In humans, this family comprises 9 different members that vary in their tissue distribution, hydrolytic activity, and phospholipid substrate specificity. Through their lipase activity, these enzymes trigger various cell-signaling events to regulate cellular functions, directly kill bacteria, or modulate inflammatory responses. In addition, some sPLA(2)'s are high affinity ligands for cellular receptors.
objectiveThis review merely scratches the surface of some of the actions of sPLA(2)s in innate immunity, inflammation, and atherosclerosis. The goal is to provide an overview of recent findings involving sPLA(2)s and to point to potential pathophysiologic mechanisms that may become targets for therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.